Regenerative Medicine for Developmental Neurodegenerative Disorders

Regenerative medicine is a subdivision of medicine that progresses methods to regrow, repair or replace diseased cells and tissues to return normal function.Regenerative medicine uses cell therapy, Nano drugs, gene therapy, recombinant proteins, and growth factors to treat neurodegenerative disease.This novel research approach has been used to attempt to treat pediatrics motor and intellectual disability such as cerebral palsy, hemolysis Kernicterus, Gilbert syndrome, phenylketonuria and spinal muscular atrophy. In recent year, the studies focused on stem cell therapy and Nano-drugs more than another type of regenerative medicine in treatment of neonatal neurodegenerative disorders. Lately effect of developed stem cells, such as amniotic epithelial stem cells and induced pluripotent stem cells, besides renowned traditional stem cells such as neural, embryonic, bone marrow mesenchyme, and human umbilical cord blood-derived stem cells in neurodegenerative disease were reported Nanotechnology occupations engineered materials or devices that interrelate with biological systems at a molecular level and could develop the treatment of neonatalneurodegenerative disorders by stimulating, responding to and cooperating with target sites to induce physiological responses whereas minimizing side-effects.The current studies show the benefits of liposome-based Nano-drugs as a novel approach to delivering active pharmaceutical ingredients and Nano-albumin fortreatment of neonatal neurodegenerative disease that involves neuroinflammation. Regenerative medicine has opened new prospective avenues in neuroregenerationof neonatal disease. Healing using stem cells and gene therapy can be beneficial in pediatric populations. Current evidence supports the valiant beneficial influenceof combination of adipose stem cells with gene therapy in kernicterus. There are now frequent examples of effective long-term treatment of animal models of neonatal neurodegeneration disorders, such as motor neuron disease, lisosomal storage disease, and spinal injury, using a variety of therapeutic genes expressed in lentiviral vectors. Important issues remain in some ranges of neural gene therapy including defining the best therapeutic gene(s), growing the specificity of delivery, modifiable expression of potentially toxic genes, and designing clinically applicable strategies. Evidence for the use of regenerative medicine clinically in pediatric motor disability and paralysis should be seen with caution because of probability side effects of these approaches such as carcinogen and rejection by immune system. Regenerative medicine in numerous frameworks deals new insights into a novel therapeutic approach for developmental neurodegenerative disease, but efficacy and safety need to be further addressed.

کلیدواژه ها:

Regenerative medicine ، Neurodegenerative disorders ، Cell therapy ، Kernicterus